Abstract:PURPOSE To explore and evaluate the protective effect of erythropoietin (EPO) on retinal cells of chemically induced diabetic rats after EPO was injected intravitreally at the onset of diabetes. METHODS Diabetes was induced in Sprague-Dawley rats by intraperitoneal injection of streptozotocin (STZ). At the onset of diabetes, a single intravitreal injection of EPO (0.05-200 ng/eye) was performed. In the following 6 weeks, the blood retinal barrier (BRB) was evaluated by Evans blue permeation (EBP). Retinal cell death in different layers was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The retinal thickness and cell counts were examined at the light microscopic level. Electron microscopy (EM) was used to scrutinize retinal vascular and neuronal injury. Neurosensory retinas of normal and diabetic rats were used as the sources of reverse transcription-polymerase chain reaction (RT-PCR) and Western blot for the detection of EPO, EPO receptor (EpoR), and products of the extracellular signal-regulated kinase (ERK) and the signal transducers and activators of transcription 5 (STAT5) pathways. The distribution of EpoR in retinal layers was demonstrated by immunohistochemistry (IHC). RESULTS In the diabetic rats, BRB breakdown was detected soon after the onset of diabetes, peaked at 2 weeks, and reached a plateau at 2 to 4 weeks. The number of TUNEL-positive cells increased in the neurosensory retina, especially, the outer nuclear layer (ONL) at 1 week after diabetes onset and reached a peak at 4 to 6 weeks. The retinal thickness and the number of cells in the ONL were reduced significantly. EM observations demonstrated vascular and photoreceptor cell death starting soon after the onset of diabetes. All these changes were largely prevented by EPO treatment. Upregulation of EpoR in the neurosensory retina was detected at both the transcriptional and protein levels 4 to 8 weeks after the onset of diabetes, whereas, the endogenous EPO levels of neurosensory retinas were essentially unchanged during the same period observed. In EPO-treated diabetic groups, EpoR expression remained at upregulated levels. Within 2 weeks of the onset of diabetes, activation of the ERK but not the STAT5 pathway was detected in the diabetic retina treated with EPO. CONCLUSIONS These data demonstrate that apoptosis is an major contributor to neuronal cell death in the early course of diabetic retinopathy (DR). The upregulation of EpoR may be a compensatory response of retinal cells and tissue to diabetic stresses. The EPO/EpoR system as a maintenance-survival mechanism of retinal neurons responds to the insults of early diabetes other than ischemia. The protective function of EPO/EpoR at the least acts through the EpoR-mediated ERK pathway. Exogenous EPO administration by intravitreal injection in early diabetes may prevent retinal cell death and protect the BRB function. Therefore, this is a novel approach for treatment of early DR.

Recombinant Human Erythropoietin Restrains Oxidative Stress in Streptozotocin-induced Diabetic Rats Exposed to Renal Ischemia Reperfusion Injury.

Erythropoietin Pretreatment Ameliorates Renal Ischaemia-Reperfusion Injury by Activating Pi3k/Akt Signalling

Activation of Nrf2/HO-1 Pathway by Glycogen Synthase Kinase-3β Inhibition Attenuates Renal Ischemia/Reperfusion Injury in Diabetic Rats

Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation.

Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina

Recombinant Human Erythropoietin Promotes Expression of HO-1 Mrna after Renal Ischemia Reperfusion Injury in Mice

Protective effect of erythropoietin preconditioning on kidney ischemia-reperfusion injury

GSK-3beta Inhibitor Induces Expression of Nrf2/TrxR2 Signaling Pathway to Protect Against Renal Ischemia/Reperfusion Injury in Diabetic Rats

Protective Effects of Erythropoietin on Myocardium against Ischemia-Reperfusion Injury

The Influence of Erythropoietin to the Ultrastructure of Retinal Neurons and Content of Retinal Glutamate in the Early Stage Diabetic Rats

Intravitreal Injection of Erythropoietin Protects Both Retinal Vascular and Neuronal Cells in Early Diabetes

Recombinant human erythropoietin pretreatment attenuates acute renal tubular injury against ischemia-reperfusion by restoring transient receptor potential channel-6 expression and function in collecting ducts.

Protection Against Ischemia/reperfusion–induced Renal Injury by Co–treatment with Erythropoietin and Sodium Selenite

Alteration of ultrastructure in retinal neurons and expression of retinal erythropoietin receptors of early stage diabetic rats with protection effects of erythropoietin

Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion

Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion.

Neuroprotection of rhEPO on Cerebral Ischemia in both Normal and Pentylenetetrazol-induced Acute Diabetic Rats

Effect of Benazepril on Oxidative Stress and Carbonyl Stress in Renal Tissues of Diabetic Rats

Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy

Erythropoietin Mitigates Diabetic Nephropathy by Restoring PINK1/Parkin-Mediated Mitophagy

Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury